This article is more than 5 years old. Information may no longer be current.

Diquafosol tetrasodium approved for treating dry eye in Japan

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

DURHAM, N.C. — The Japanese Ministry of Health, Labour and Welfare has approved diquafosol tetrasodium for treating dry eye, according to a press release from co-developers Santen Pharmaceutical and Inspire Pharmaceuticals.

In clinical trials conducted in Japan, long-term administration of Diquas (diquafosol tetrasodium ophthalmic solution 3%) demonstrated the ability to improve dry eye symptoms with no serious ocular or systemic adverse reactions, the release said.

Diquafosol tetrasodium ophthalmic solution 3% is the first approved P2Y2 receptor agonist to be formulated as an ophthalmic solution.

Follow OSNSuperSite.com on Twitter.